You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》里昂上調康寧傑瑞製藥-B(09966.HK)目標價至21元 評級「買入」
阿思達克 08-31 11:29
里昂發表報告指,康寧傑瑞製藥-B(09966.HK)研發的藥品仍處臨床階段,預期不會在明年前有產品推出,因此今年上半年錄虧損1.03億元人民幣,對比市場估計今年虧損5.75億元人民幣。

該行表示,集團治療膽管癌新藥KN035(Envafolimab)的臨床進展令人鼓舞,料於今年第四季作生物製品上市申請(BLA),而治療非小細胞肺癌的另一新藥KN046亦進入三期臨床。

里昂將康寧傑瑞製藥今年上半年的數據更新至模型,並上調其股份目標價,由17.39元升至21元,評級維持「買入」。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account